If you are experiencing problems downloading PDF or HTML fulltext, our helpdesk recommend clearing your browser cache and trying again. If you need help in clearing your cache, please click here . Still need help? Email help@ingentaconnect.com

Tiotropium for Treatment of Stable COPD: A Meta-analysis of Clinically Relevant Outcomes

The full text article is not available for purchase.

The publisher only permits individual articles to be downloaded by subscribers.


OBJECTIVE: To systematically review recent evidence on the effectiveness of tiotropium versus placebo, ipratropium, and long-acting 2 agonists on outcomes relevant to patients with stable COPD, including health-related quality of life, dyspnea, exacerbations and hospitalizations. METHODS: Our inclusion criteria for trials were: ≥ 12 weeks; compared tiotropium to placebo, ipratropium, or long-acting  agonists; patients ≥ 40 y old and with stable COPD. Sixteen trials (16,301 patients) met the inclusion criteria. RESULTS: Tiotropium improved health-related quality of life (measured with St George's Respiratory Questionnaire) compared to placebo (odds ratio [OR] 1.61, 95% CI 1.38‐1.88, P < .001) and ipratropium (OR 2.03, 95% CI 1.34‐3.07, P = .001). Tiotropium also improved dyspnea (measured with the Transitional Dyspnea Index) compared to placebo (OR 1.96, 95% CI 1.58‐2.44, P < .001) and ipratropium (OR 2.10, 95% CI 1.28‐3.44, P = .003). Tiotropium decreased the likelihood of an exacerbation (OR 0.83, 95% CI 0.72‐0.94, P = .004) and related hospitalizations (OR 0.89, 95% CI 0.80‐0.98, P = .02) but not serious adverse events (OR 1.06, 95% CI 0.97‐1.17, P = .19), compared to placebo. The cumulative incidence of dry mouth was 7.4% with tiotropium, compared to 3.9% with ipratropium, 1.6% with salmeterol, and 2.0% with placebo. CONCLUSIONS: In stable COPD, tiotropium showed superior efficacy in improving quality of life and dyspnea, compared to placebo and ipratropium. However, tiotropium's differences with salmeterol were less clear.

Keywords: COPD; dyspnea; exacerbations; hospitalization; meta-analysis; quality of life; tiotropium

Document Type: Research Article

DOI: http://dx.doi.org/10.4187/respcare.00852

Affiliations: Department of Health Professions, Manchester Metropolitan University, Manchester, United Kingdom, UK

Publication date: April 1, 2011

More about this publication?
Related content



Share Content

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more